Six Anaphylaxis Reports, One Batch and Visible Particulates
Over three weeks the pharmacist at a county referral hospital compiles six reports of anaphylaxis, two of them fatal, following intravenous ceftriaxone 1 g from batch CEF-2291 (expiry 08/2026). All six patients also received intramuscular diclofenac, and one has a documented penicillin allergy. The hospital still holds 240 vials of the batch, but the distributor supplied 40 other facilities and about 12,000 vials were released. When 20 vials from the batch are reconstituted, visible particles appear in three. The hospital's medicines and therapeutics committee wants to switch to another brand immediately and 'leave the paperwork until the case series is complete', arguing that anaphylaxis is already in the ceftriaxone label, so nothing new needs reporting. The pharmacist is unsure whether this is a pharmacovigilance issue, a quality defect, or both, and who must be told first.
1. Is this a safety report, a quality defect, or both? How do you assess causality?
Read the worked answer
Both, and they run in parallel. The deaths are serious adverse events requiring individual case safety reports; the visible particulates are a quality defect requiring immediate notification to the PPB's market surveillance and quality functions. Neither route waits for the other.
Causality, case by case. Use a structured method (WHO-UMC or Naranjo). Temporality is plausible; anaphylaxis is a recognised ceftriaxone reaction, so it is expected; but each case has confounders - diclofenac, and a documented penicillin allergy in one patient. Individually, several cases may score only 'possible'.
Then aggregate. A cluster in time, from a single batch, with visible particulate contamination, raises a product-quality explanation that individual causality assessment cannot capture. Particulates can precipitate anaphylactoid reactions. A rate and severity exceeding what the label predicts is a signal, regardless of expectedness.
Expectedness does not remove the duty to report - it shapes the action: label review, risk management plan, and batch investigation. The committee's proposal to delay reporting until the series is complete is unsafe and non-compliant.
2. Do you recall? At what class? Set out the immediate actions and communications.
Read the worked answer
Yes - recall now, do not wait for a completed case series. Two deaths plus visible particulates in three of 20 vials gives a reasonable probability of serious adverse health consequences or death: treat as a Class I recall pending laboratory results, and downgrade only if testing supports it.
Immediate actions. Quarantine the 240 hospital vials; stop use of the batch; notify the PPB and the distributor the same day; instruct the distributor to stop supply and trace all 40 facilities; issue a hospital and facility alert with the batch number and expiry; arrange alternative ceftriaxone supply so treatment is not interrupted; retrieve and segregate stock; send retained vials from the same batch to the national quality control laboratory for particulate matter, sterility, assay and related substances, with chain-of-custody documentation.
Communications. Factual and non-speculative: what is known, what is being done, and how to report reactions. Do not name a culprit before testing. Advise clinicians to report any reaction from the batch and to record the batch number on every report.
Widen the review. Check other batches from the same manufacturer and the same API source, and consider whether the supplier's other products need sampling.